You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 4, 2024

~ Buy the RETEVMO (selpercatinib) Drug Profile, 2024 PDF Report in the Report Store ~

RETEVMO Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Retevmo patents expire, and what generic alternatives are available?

Retevmo is a drug marketed by Loxo Oncol Eli Lilly and is included in two NDAs. There are five patents protecting this drug and one Paragraph IV challenge.

This drug has one hundred and thirty-four patent family members in forty-one countries.

The generic ingredient in RETEVMO is selpercatinib. One supplier is listed for this compound. Additional details are available on the selpercatinib profile page.

DrugPatentWatch® Generic Entry Outlook for Retevmo

Retevmo was eligible for patent challenges on May 8, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 10, 2037. This may change due to patent challenges or generic licensing.

There is one Paragraph IV patent challenge for this drug. This may lead to patent invalidation or a license for generic production.

Indicators of Generic Entry

< Available with Subscription >

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for RETEVMO?
  • What are the global sales for RETEVMO?
  • What is Average Wholesale Price for RETEVMO?
Summary for RETEVMO
International Patents:134
US Patents:5
Applicants:1
NDAs:2
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 34
Clinical Trials: 5
Patent Applications: 45
Drug Prices: Drug price information for RETEVMO
What excipients (inactive ingredients) are in RETEVMO?RETEVMO excipients list
DailyMed Link:RETEVMO at DailyMed
Drug patent expirations by year for RETEVMO
Drug Prices for RETEVMO

See drug prices for RETEVMO

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for RETEVMO
Generic Entry Dates for RETEVMO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
CAPSULE;ORAL
Generic Entry Dates for RETEVMO*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for RETEVMO

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Massachusetts General HospitalPhase 2
Eli Lilly and CompanyPhase 2
Southwest Oncology GroupPhase 2

See all RETEVMO clinical trials

Paragraph IV (Patent) Challenges for RETEVMO
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
RETEVMO Capsules selpercatinib 40 mg and 80 mg 213246 1 2024-05-08

US Patents and Regulatory Information for RETEVMO

RETEVMO is protected by forty-five US patents and ten FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of RETEVMO is ⤷  Sign Up.

This potential generic entry date is based on patent ⤷  Sign Up.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting RETEVMO

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Crystalline forms
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: ADULT AND PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAS PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATMENT OF ADULT OR PEDIATRIC PATIENTS 2 YEARS OF AGE OR OLDER WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS PAPILLARY THYROID CANCER

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS RECURRENT THYROID CANCER

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS MEDULLARY THYROID CANCER

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY, WHEREIN THE CANCER IS DIFFERENTIATED THYROID CANCER

Formulations of 6-(2-hydroxy-2-methylpropxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-- diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-A]pyridine-3-carb- onitrile
Patent Number: ⤷  Sign Up
Patent Expiration: ⤷  Sign Up
Patented Use: TREATING ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE REFRACTORY DIFFERENTIATED THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND ARE RADIOACTIVE IODINE-REFRACTORY

FDA Regulatory Exclusivity protecting RETEVMO

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Sign Up

INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
Exclusivity Expiration: ⤷  Sign Up

INDICATED FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET-MUTANT MEDULLARY THYROID CANCER (MTC) WHO REQUIRE SYSTEMIC THERAPY
Exclusivity Expiration: ⤷  Sign Up

ADULT AND PEDIATRIC PATIENTS 12 YEARS OF AGE AND OLDER WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE THYROID CANCER WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WITH ADVANCED OR METASTATIC MEDULLARY THYROID CANCER (MTC) WITH A RET MUTATION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE TO LESS THAN 12 YEARS OF AGE WITH ADVANCED OR METASTATIC THYROID CANCER WITH A RET GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST, WHO REQUIRE SYSTEMIC THERAPY AND WHO ARE RADIOACTIVE IODINE-REFRACTORY (IF RADIOACTIVE IODINE IS APPROPRIATE)
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORS WITH A RET GENE FUSION THAT HAVE PROGRESSED ON OR FOLLOWING PRIOR SYSTEMIC TREATMENT OR WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
Exclusivity Expiration: ⤷  Sign Up

TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WITH A REARRANGED DURING TRANSFECTION (RET) GENE FUSION, AS DETECTED BY AN FDA-APPROVED TEST
Exclusivity Expiration: ⤷  Sign Up

NEW PATIENT POPULATION
Exclusivity Expiration: ⤷  Sign Up

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Loxo Oncol Eli Lilly RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up Y Y ⤷  Sign Up
Loxo Oncol Eli Lilly RETEVMO selpercatinib TABLET;ORAL 218160-001 Apr 10, 2024 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Loxo Oncol Eli Lilly RETEVMO selpercatinib CAPSULE;ORAL 213246-002 May 8, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Loxo Oncol Eli Lilly RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Loxo Oncol Eli Lilly RETEVMO selpercatinib CAPSULE;ORAL 213246-001 May 8, 2020 RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for RETEVMO

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Eli Lilly Nederland B.V. Retsevmo selpercatinib EMEA/H/C/005375
Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and older with advanced RET-mutant medullary thyroid cancer (MTC)advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET inhibitoradvanced RET fusion-positive thyroid cancer who require systematic therapy following prior treatment
Authorised no no no 2021-02-11
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

International Patents for RETEVMO

When does loss-of-exclusivity occur for RETEVMO?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Patent: 9919
Patent: COMPUESTOS PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDA COMO INHIBIDORES DE RET QUINASA
Estimated Expiration: ⤷  Sign Up

Patent: 9920
Patent: COMPUESTOS PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDA COMO INHIBIDORES DE RET QUINASA
Estimated Expiration: ⤷  Sign Up

Patent: 3760
Patent: FORMAS CRISTALINAS
Estimated Expiration: ⤷  Sign Up

Australia

Patent: 17342022
Patent: Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 17342027
Patent: Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 18348161
Patent: Crystalline forms
Estimated Expiration: ⤷  Sign Up

Brazil

Patent: 2019007143
Patent: compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
Estimated Expiration: ⤷  Sign Up

Patent: 2019007144
Patent: compostos de pirazolo[1,5-a]piridina substituídos como inibidores da ret cinase
Estimated Expiration: ⤷  Sign Up

Patent: 2020005463
Patent: formas cristalinas
Estimated Expiration: ⤷  Sign Up

Canada

Patent: 39760
Patent: COMPOSES SUBSTITUES DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 39912
Patent: COMPOSES DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUES EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 79012
Patent: FORMES CRISTALLINES (CRYSTALLINE FORMS)
Estimated Expiration: ⤷  Sign Up

Chile

Patent: 19000941
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
Estimated Expiration: ⤷  Sign Up

Patent: 19000942
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret.
Estimated Expiration: ⤷  Sign Up

China

Patent: 0177786
Patent: 经取代的吡唑并[1,5-A]吡啶化合物作为RET激酶抑制剂 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 0382494
Patent: 经取代的吡唑并[1,5-A]吡啶化合物作为RET激酶抑制剂 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 1278822
Patent: 结晶形式 (CRYSTALLINE FORMS)
Estimated Expiration: ⤷  Sign Up

Patent: 4163437
Patent: 经取代的吡唑并[1,5-A]吡啶化合物作为RET激酶抑制剂 (Substituted pyrazolo [1, 5-a] pyridine compounds as RET kinase inhibitors)
Estimated Expiration: ⤷  Sign Up

Colombia

Patent: 19004649
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
Estimated Expiration: ⤷  Sign Up

Patent: 19004650
Patent: Compuestos de pirazolo[1,5-a]piridina sustituidos como inhibidores de la quinasa ret
Estimated Expiration: ⤷  Sign Up

Costa Rica

Patent: 190218
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 190224
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Croatia

Patent: 0201008
Estimated Expiration: ⤷  Sign Up

Patent: 0221154
Estimated Expiration: ⤷  Sign Up

Cyprus

Patent: 23201
Estimated Expiration: ⤷  Sign Up

Denmark

Patent: 23301
Estimated Expiration: ⤷  Sign Up

Patent: 23302
Estimated Expiration: ⤷  Sign Up

Dominican Republic

Patent: 019000090
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷  Sign Up

Patent: 019000091
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷  Sign Up

Ecuador

Patent: 19032676
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷  Sign Up

Patent: 19033052
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷  Sign Up

Eurasian Patent Organization

Patent: 5568
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ (SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 7208
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ (SUBSTITUTED PYRAZOLO[1,5-a]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 1990939
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
Estimated Expiration: ⤷  Sign Up

Patent: 1990940
Patent: ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-a]ПИРИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RET КИНАЗЫ
Estimated Expiration: ⤷  Sign Up

Patent: 2090695
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ
Estimated Expiration: ⤷  Sign Up

European Patent Office

Patent: 23301
Patent: COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 23302
Patent: COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 94854
Patent: FORMES CRISTALLINES (CRYSTALLINE FORMS)
Estimated Expiration: ⤷  Sign Up

Patent: 53939
Patent: COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 44735
Patent: COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Hungary

Patent: 51424
Estimated Expiration: ⤷  Sign Up

Patent: 60089
Estimated Expiration: ⤷  Sign Up

Israel

Patent: 5916
Patent: תרכובות פיראזולו[1,5-a]פירידין מותמר כמעכבי ret קינאז (Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors)
Estimated Expiration: ⤷  Sign Up

Patent: 5918
Patent: תרכובות פיראזולו[1,5-a]פירידין מותמר כמעכבי ret קינאז (Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors)
Estimated Expiration: ⤷  Sign Up

Patent: 3730
Patent: צורות גבישיות (Crystalline forms)
Estimated Expiration: ⤷  Sign Up

Patent: 7576
Patent: תרכובות פיראזולו[1,5-a]פירידין מותמר כמעכבי ret קינאז (Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors)
Estimated Expiration: ⤷  Sign Up

Japan

Patent: 76446
Estimated Expiration: ⤷  Sign Up

Patent: 45070
Estimated Expiration: ⤷  Sign Up

Patent: 75399
Estimated Expiration: ⤷  Sign Up

Patent: 79303
Estimated Expiration: ⤷  Sign Up

Patent: 11654
Estimated Expiration: ⤷  Sign Up

Patent: 02365
Estimated Expiration: ⤷  Sign Up

Patent: 19533670
Patent: RETキナーゼ阻害剤としての置換ピラゾロ[1,5−A]ピリジン化合物
Estimated Expiration: ⤷  Sign Up

Patent: 20503247
Patent: RETキナーゼ阻害剤としての置換ピラゾロ[1,5−A]ピリジン化合物
Estimated Expiration: ⤷  Sign Up

Patent: 20536900
Patent: 結晶形態
Estimated Expiration: ⤷  Sign Up

Patent: 21035944
Patent: RETキナーゼ阻害剤としての置換ピラゾロ[1,5−A]ピリジン化合物 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 22062168
Patent: RETキナーゼ阻害剤としての置換ピラゾロ[1,5-A]ピリジン化合物
Estimated Expiration: ⤷  Sign Up

Patent: 22116108
Patent: RETキナーゼ阻害剤としての置換ピラゾロ[1,5-A]ピリジン化合物
Estimated Expiration: ⤷  Sign Up

Patent: 23134580
Patent: RETキナーゼ阻害剤としての置換ピラゾロ[1,5-A]ピリジン化合物 (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Jordan

Patent: 0190076
Patent: مركبات بيرازولو [1، 5-A]بيريدين بها استبدال كمثبطات كيناز RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 0190077
Patent: مركبات بيرازولو [1، 5-A]بيريدين بها استبدال كمثبطات كيناز RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Lithuania

Patent: 23301
Estimated Expiration: ⤷  Sign Up

Patent: 23302
Estimated Expiration: ⤷  Sign Up

Malaysia

Patent: 5573
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

Mexico

Patent: 19004204
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET. (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.)
Estimated Expiration: ⤷  Sign Up

Patent: 19004205
Patent: COMPUESTOS DE PIRAZOLO[1,5-4]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET. (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.)
Estimated Expiration: ⤷  Sign Up

Patent: 20003552
Patent: FORMAS CRISTALINAS. (CRYSTALLINE FORMS.)
Estimated Expiration: ⤷  Sign Up

Patent: 20011250
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET. (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS.)
Estimated Expiration: ⤷  Sign Up

Moldova, Republic of

Patent: 23301
Estimated Expiration: ⤷  Sign Up

Patent: 23302
Estimated Expiration: ⤷  Sign Up

Morocco

Patent: 462
Patent: Composés substitués de pyrazolo[1,5-a]pyridine en tant qu'inhibiteurs de la kinase ret
Estimated Expiration: ⤷  Sign Up

Patent: 463
Patent: COMPOSÉS DE PYRAZOLO[1,5-A]PYRIDINE SUBSTITUÉS EN TANT QU'INHIBITEURS DE LA KINASE RET
Estimated Expiration: ⤷  Sign Up

Patent: 675
Patent: COMPOSÉS SUBSTITUÉS DE PYRAZOLO[1,5-A]PYRIDINE EN TANT QU'INHIBITEURS DE LA KINASE RET
Estimated Expiration: ⤷  Sign Up

New Zealand

Patent: 2793
Patent: Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors
Estimated Expiration: ⤷  Sign Up

Peru

Patent: 190918
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷  Sign Up

Patent: 191613
Patent: COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET
Estimated Expiration: ⤷  Sign Up

Philippines

Patent: 019500775
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 019500776
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

Poland

Patent: 23301
Estimated Expiration: ⤷  Sign Up

Patent: 23302
Estimated Expiration: ⤷  Sign Up

Portugal

Patent: 23301
Estimated Expiration: ⤷  Sign Up

Patent: 23302
Estimated Expiration: ⤷  Sign Up

Saudi Arabia

Patent: 9401541
Patent: [1، 5-A] مركبات بيرازولو كيناز RET بيريدين بها استبدال كمثبطات (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 9401544
Patent: [1، 5-A] مركبات بيرازولو بيريدين بها استبدال كمثبطات كيناز معاد ترتيبه أثناء نقل العدوى (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS REARRANGED DURING TRANSFECTION KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Serbia

Patent: 536
Patent: SUPSTITUISANA PIRAZOLO[1,5-A]PIRIDIN JEDINJENJA KAO INHIBITORI RET KINAZE (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 510
Patent: SUPSTITUISANA PIRAZOLO[1,5-A]PIRIDIN JEDINJENJA KAO INHIBITORI RET KINAZE (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Singapore

Patent: 201903144P
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 201903187W
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

Slovenia

Patent: 23301
Estimated Expiration: ⤷  Sign Up

Patent: 23302
Estimated Expiration: ⤷  Sign Up

South Africa

Patent: 2004040
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

South Korea

Patent: 2143899
Estimated Expiration: ⤷  Sign Up

Patent: 2287752
Estimated Expiration: ⤷  Sign Up

Patent: 2410437
Estimated Expiration: ⤷  Sign Up

Patent: 190076976
Patent: RET 키나제 억제제로서의 치환된 피라졸로[1,5-A]피리딘 화합물
Estimated Expiration: ⤷  Sign Up

Patent: 190077389
Patent: RET 키나제 억제제로서의 치환된 피라졸로[1,5-A]피리딘 화합물
Estimated Expiration: ⤷  Sign Up

Patent: 200051744
Patent: 결정질 형태
Estimated Expiration: ⤷  Sign Up

Spain

Patent: 05087
Estimated Expiration: ⤷  Sign Up

Patent: 26136
Estimated Expiration: ⤷  Sign Up

Taiwan

Patent: 04148
Estimated Expiration: ⤷  Sign Up

Patent: 52098
Estimated Expiration: ⤷  Sign Up

Patent: 91053
Estimated Expiration: ⤷  Sign Up

Patent: 1825488
Patent: Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 1827428
Patent: Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
Estimated Expiration: ⤷  Sign Up

Patent: 1922741
Patent: Crystalline forms
Estimated Expiration: ⤷  Sign Up

Tunisia

Patent: 19000107
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

Patent: 19000110
Patent: SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS
Estimated Expiration: ⤷  Sign Up

Ukraine

Patent: 5030
Patent: ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ RET-КІНАЗИ (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Patent: 5032
Patent: ЗАМІЩЕНІ ПІРАЗОЛО[1,5-a]ПІРИДИНОВІ СПОЛУКИ ЯК ІНГІБІТОРИ RЕТ-КІНАЗИ (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS)
Estimated Expiration: ⤷  Sign Up

Uruguay

Patent: 925
Patent: FORMAS CRISTALINAS
Estimated Expiration: ⤷  Sign Up

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RETEVMO around the world.

Country Patent Number Title Estimated Expiration
Jordan P20190076 مركبات بيرازولو [1، 5-A]بيريدين بها استبدال كمثبطات كيناز RET (SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS) ⤷  Sign Up
Ecuador SP19033052 COMPUESTOS DE PIRAZOLO[1,5-A]PIRIDINA SUSTITUIDOS COMO INHIBIDORES DE LA QUINASA RET ⤷  Sign Up
Tunisia 2019000107 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ⤷  Sign Up
Spain 2805087 ⤷  Sign Up
Malaysia 195573 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.